<h3>Objective:</h3> The MS-LINK Outcomes Study is a prospective longitudinal multi-center observational study focused on patient-reported outcomes (PROs) collection, which aims to develop a comprehensive data source on patients with multiple sclerosis (MS). <h3>Background:</h3> PROs are currently underutilized and can be leveraged in conjunction with provider-reported and healthcare utilization data to improve our understanding of MS disease progression and treatment, particularly in diverse subpopulations. <h3>Design/Methods:</h3> The study aims to enroll ≥2000 patients from 8–10 sites in North America followed for 3 years. Patient medical history, demographics, clinical and functional outcomes, and PROs are collected digitally at baseline and subsequent regular intervals. The objective of the study is to understand PRO changes over time and to identify PRO correlations to clinical and functional outcomes in multiple sclerosis. <h3>Results:</h3> As of October 2022, we report on 796 patients. Mean age of the cohort is 50, 81.7% are female, 90.5% with RRMS, and mean disease duration of 13.8 years. The study population is sociodemographically diverse with approximately 25% of patients self-reporting as non-white, and 18% self-reporting Hispanic or other ethnicity. DMT use is diverse; approximately 46% self-report no current DMT use. Baseline mean PDDS score is 1.9 (SD = 2.1). Mean baseline PROMIS Fatigue (55.7, SD = 10.4) and Anxiety (52.5, SD = 10.1) scores are slightly elevated relative to the general population, while PROMIS Physical Function (42.6, SD = 11.4) and Cognitive Function (44.8, SD = 10.4) scores are slightly depressed. Baseline PRO completion rates of nearly 89% indicate high patient engagement. <h3>Conclusions:</h3> The MS-LINK Outcomes Study uniquely utilizes a decentralized trial approach. Use of digital dashboards provide real time tracking of outcomes and a comprehensive view of the patient experience. The diverse patient population improves the generalizability of study findings, facilitates subgroup analyses, and potential future sub-studies. <b>Disclosure:</b> Dr. English has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for biogen idec. Dr. English has received personal compensation in the range of $500-$4,999 for serving as a Consultant for bristol myer squibb. Dr. English has received personal compensation in the range of $500-$4,999 for serving as a Consultant for genentech. Dr. English has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for sanofi genzyme. Dr. English has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for biogen idec. Dr. English has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for genzyme. Dr. English has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for genentech. Dr. English has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for bristol myer squibb. Dr. English has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therpeutics. Dr. English has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. English has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for swift currie. Dr. English has received intellectual property interests from a discovery or technology relating to health care. Dr. Tornatore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Serono. Dr. Tornatore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Tornatore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Tornatore has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Riser has nothing to disclose. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche Genentech. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi Genzyme. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS / Celgene. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for EMD Serono. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viela Bio. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape, LLC. The institution of Dr. Freeman has received research support from Genentech. The institution of Dr. Freeman has received research support from NIH/NINDS. The institution of Dr. Freeman has received research support from NIH/NINDS. The institution of Dr. Freeman has received research support from PCORI. The institution of Dr. Freeman has received research support from EMD Serono. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving as a Participant in educational interview with Multiple Sclerosis Association of America. Dr. Sloane has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for biogen. Dr. Sloane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Sloane has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Piette has received personal compensation for serving as an employee of EMD Serono, Inc. An immediate family member of Dr. Piette has received personal compensation for serving as an employee of OnCorps. An immediate family member of Dr. Piette has received personal compensation for serving as an employee of Exosome Diagnostics. Ms. Caon has received personal compensation for serving as an employee of EMD Serono. Ms. Livingston has received personal compensation for serving as an employee of EMD Serono, Inc. Ms. Livingston has stock in EMD Serono, Inc. Ms. Livingston has stock in Biogen.